# Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

> **NCT01222299** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 89 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** bepotastine besilate nasal product - low dose
- **DRUG:** bepotastine besilate nasal product - medium dose
- **DRUG:** bepotastine besilate nasal product - high dose
- **DRUG:** placebo comparator nasal product

## Key facts

- **NCT ID:** NCT01222299
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222299, "Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01222299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*